Abbott Labs' Peer Premium Seen Warranted
15th Sep 2005, 14:48 GMT
Banc of America maintained a buy rating on Abbott Labs after a FDA advisory panel rejected the company's prostate cancer drug Xinlay.
Latest news from Government/ Industry Regulation News from myHealthcareNews.com:
- PLC Systems to Show RenalGuard at Medica 2006
- National Public Health Summit Targets Cervical Cancer Elimination
- MediPurpose Announces Exclusive Distribution Agreement for Sangofer Blood Separation Product
- Portrait PSR3 by Rhytec named in TIME Magazine's 2006 Skin Technology Story
- Pharsight Invited to Present on Model-Based Drug Development rd Annual Australian Health and Medical Research Congress
- Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress of the Societe Internationale d'Urologie
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ
- Sector Election Boosts Stem Cells
- AUDIO From Medialink and AARP: Voters' Call for Change Signals New Directions for Health Care
- Schering-Plough CEO Calls on New Congress to 'Do What Is Right' for the Patient, Calls for 'Scorecards' to Rate Managed Care Performance